Indications for and use of long-acting injectable antipsychotics: consideration from an inpatient setting.
Studies have examined the differences in sociodemographic/clinical characteristics between patients on long-acting injectable (LAI) versus oral medications. However, most studies did not focus specifically on patients for whom LAIs would clearly be indicated. We performed a chart review of patients with schizophrenia or schizoaffective disorder. Patients were categorized as having an 'indication for an LAI' or not on the basis of their adherence history. Patients for whom an LAI was indicated and prescribed on discharge were then compared with similar patients for whom an LAI was not prescribed. Of 305 charts reviewed, consisting of 279 unique patients, 27.2% were judged to have an indication for an LAI (n=76), but only 32.9% of these (n=25) were discharged on an LAI. In the multiregression model, being African American, residing in a psychiatric residence, having a previous history of an LAI trial, and being treated with a higher antipsychotic dose were predictive of LAI prescription. It is important to focus on the population who are not likely to receive an LAI, but who have such indications for treatment.
aThe Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks bHofstra Northwell School of Medicine, Hempstead cThe Feinstein Institute for Medical Research, Manhasset dWeill Cornell Medical College New York-Presbyterian Hospital/Westchester Division, White Plains eNew York University School of Medicine, New York, New York fDepartment of Mathematics, Hofstra, University, Hempstead, New York gEastside Medical Center, Snellville, Georgia hBaylor Scott and White Psychiatry, Irving, Texas, USA iDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Taishiro
T
Kishimoto
Sohag
S
Sanghani
Mark J
MJ
Russ
Akeem N
AN
Marsh
Joshua
J
Morris
Suparna
S
Basu
Majnu
M
John
John M
JM
Kane
D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D003692:Delayed-Action Preparations / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007297:Inpatients; D008297:Male; D055118:Medication Adherence; D011618:Psychotic Disorders / Q000188:drug therapy*; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations